Nolato AB (NOLA-B) Fair Value & Analysis
Healthcare · SE · Market cap 13.1B SEK
Fair value as of: Jul 11, 2026
From 26 valuation models · updated 10 days ago
Share price −4.1% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 45.31 – kr 61.60 · fair‑value band kr 40.97 – kr 68.29 · the kr 47.50 price screens below the kr 54.63 fair value. As of Jul 11, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Nolato AB (NOLA-B) currently trades at kr 47.50, while our model-based Fair Value estimate is kr 54.63, implying the stock looks roughly 15.0% undervalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Nolato AB generated revenue of 9.4B SEK at a net margin of 8.1%. Revenue declined 3.9% year over year. It earns a return on equity of 13.3%. Net debt stands at 972M SEK. Fundamentals as of Jul 11, 2026
Our scenario range runs from kr 40.97 (bear case) to kr 68.29 (bull case); at kr 47.50, the current price sits within that range. The share trades about 24% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 15%, NOLA-B screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 11, 2026. TTM = trailing twelve months.
About the company
Nolato AB (publ) develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally. It operates through the Medical Solutions and Engineered Solutions segments. The company offers catheter balloons; breathing bags; non-conductive sealing and damping silicone products; primary plastic packaging for medicines; and crimp and dropper bottles. It also provides thermal heating pads, gap fillers, and paste under the Compatherm brand; Autolys M products, deep well plates, microtubes, PCR/qPCR products, pipettes and slim-line pipette tips, vial HP, and quality grades under the TreffLab by Nolato; and electromagnetic compatibility (EMC) products, including Compashield molded and extruded electromagnetic interference (EMI) shielding gaskets, Trishield, and MIL SPEC EMI shielding products. In addition, the company offers laboratory products, such as boxes with integrated lids; containers with hinged lids; sampling and …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Nolato AB reported revenue of kr 9.5B in FY2025 versus kr 11.6B in FY2021, a compound −5.0%/yr. Reported net income was kr 777M in FY2025, compounding −9.5%/yr from FY2021.
Is NOLA-B fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $90.53 | $79.67 | -12% |
| Stryker Corporation SYK | $310.00 | $186.28 | -40% |
| Medtronic plc MDTC34 | R$211.05 | R$29.52 | -86% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
| Koninklijke Philips N.V PHG | $26.61 | $12.54 | -53% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Nolato AB (NOLA-B) undervalued?
What is the fair value of NOLA-B?
What is the quality score of NOLA-B?
What is the revenue of Nolato AB (NOLA-B)?
What is the net profit margin of NOLA-B?
Does Nolato AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Nolato AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.